These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32058)

  • 21. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
    Quock RM; Lucas TS; Hartl TJ
    Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolyl-leucyl-glycinamide (PLG): inhibition of offensive aggression in mice.
    Kavaliers M; Hirst M
    Life Sci; 1986 Nov; 39(19):1729-35. PubMed ID: 2877382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans.
    Ehrensing RH; Kastin AJ; Michell GF
    Pharmacol Biochem Behav; 1984 Dec; 21(6):975-8. PubMed ID: 6151672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonism of dermorphin-induced catalepsy with naloxone, TRH-analog CG3703 and the benzodiazepine antagonist, Ro 15-1788.
    Paakkari P; Feuerstein G
    Neuropharmacology; 1988 Oct; 27(10):1007-12. PubMed ID: 2907115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
    Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.
    Mishra RK; Chiu S; Chiu P; Mishra CP
    Methods Find Exp Clin Pharmacol; 1983; 5(4):203-33. PubMed ID: 6136640
    [No Abstract]   [Full Text] [Related]  

  • 27. Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels.
    Petersson M; Uvnäs-Moberg K
    Physiol Behav; 2004 Dec; 83(3):475-81. PubMed ID: 15581670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
    Xu DL; Yu WC; Pan GB; Chen SD
    Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
    Mishra RK
    Nutr Health; 1984; 3(3):175-87. PubMed ID: 6152723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
    Ott MC; Costain WJ; Mishra RK; Johnson RL
    Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chronic treatment with morphine on the binding of 3H-N-n-propylnorapomorphine to striatal membranes of rats: influence of prolyl-leucyl-glycinamide.
    Das S; Bhargava HN
    Pharmacology; 1985; 31(5):241-7. PubMed ID: 2866551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
    Bhargava HN; Kim HS
    J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
    Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
    J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The action of prolyl-leucyl-glycinamide (PLG) on the nigrostriatal pathway of the rat.
    Pereira JS; Andrade LA; Bertolucci PH; Lima JG; Ferraz HB
    Arq Neuropsiquiatr; 1990 Jun; 48(2):156-60. PubMed ID: 1979732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
    Verma V; Mann A; Costain W; Pontoriero G; Castellano JM; Skoblenick K; Gupta SK; Pristupa Z; Niznik HB; Johnson RL; Nair VD; Mishra RK
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1228-36. PubMed ID: 16126839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptides and social behavior of rats tested in dyadic encounters.
    Niesink RJ; van Ree JM
    Neuropeptides; 1984 Nov; 4(6):483-96. PubMed ID: 6151143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropharmacological studies with thyrotropin releasing hormone (TRH) and other hypothalamic hormones.
    Kruse H
    Naunyn Schmiedebergs Arch Pharmacol; 1977; 297 Suppl 1():S61-2. PubMed ID: 16226
    [No Abstract]   [Full Text] [Related]  

  • 38. Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse.
    Mycroft FJ; Wei ET
    Peptides; 1984; 5(5):883-7. PubMed ID: 6150468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotensin induces catalepsy in mice.
    Snijders R; Kramarcy NR; Hurd RW; Nemeroff CB; Dunn AJ
    Neuropharmacology; 1982 May; 21(5):465-8. PubMed ID: 6810195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypothalamic peptide hormone, prolyl-leucyl-glycinamide and analog, inhibit tolerance to the analgesic and locomotor depressant but not to the locomotor stimulant effects of morphine in the mouse.
    Bhargava HN
    Neuropharmacology; 1982 Mar; 21(3):227-33. PubMed ID: 6122186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.